Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 1(4)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04357821Phase 1Active Not Recruiting

Combinatorial Therapy to Induce an HIV Remission

Role: collaborator

NCT02668770Phase 1Active Not Recruiting

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Role: collaborator

NCT02077868Phase 3Unknown

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

Role: lead

NCT02200081Phase 2Completed

Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC

Role: lead

NCT01265368Phase 1Completed

A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)

Role: lead

NCT01208194Phase 2Completed

Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma

Role: lead

NCT01982747Phase 1Completed

A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

Role: lead

All 7 trials loaded